A first-in-human Phase I non-randomized open-label multicenter dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6

Brief description of study

A first-in-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.